

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**China Health Group Limited**  
**中國衛生集團有限公司**

*(Carrying on business in Hong Kong as CHG HS Limited)*

*(Incorporated in Bermuda with limited liability)*

*(Stock Code: 673)*

**PROPOSED SHARE CONSOLIDATION**

**SHARE CONSOLIDATION**

The board (the “**Board**”) of directors (the “**Directors**”) of China Health Group Limited (the “**Company**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Company intends to conduct a consolidation (the “**Share Consolidation**”) of the existing ordinary shares in the capital of the Company of par value of HK\$0.10 each (the “**Existing Shares**”).

Pursuant to Rule 13.64 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), where the market price of the securities of an issuer approaches the extremities of HK\$0.01 or HK\$9,995.00, the issuer may be required either to change the trading method or to proceed with a consolidation or splitting of its securities. According to the “Guide on Trading Arrangements for Selected Types of Corporate Actions” issued by the Stock Exchange on 28 November 2008 and updated on 1 October 2020, market price of the securities of an issuer at a level less than HK\$0.10 will be considered as trading at extremity as referred to under Rule 13.64 of the Listing Rules.

As the Existing Shares have been traded at below HK\$0.10 most of the time in the past two years, the Board considers that the Share Consolidation should enable the Company to better comply with the trading requirements under the Listing Rules.

Further details of the Share Consolidation including the expected timetable, detailed reasons, terms and conditions, procedures and arrangements will be disclosed in a further announcement of the Company.

**Shareholders should take note that the Share Consolidation is conditional upon the fulfilment of conditions. Therefore, the Share Consolidation may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and if they are in any doubt about their position, they should consult their professional advisers.**

By order of the Board  
**China Health Group Limited**  
**Zhang Fan**  
*Chairman and Executive Director*

Hong Kong, 10 June 2022

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.*